The 6 analysts offering 12-month price forecasts for Orchard Therapeutics PLC have a median target of 4.50, with a high estimate of 5.00 and a low estimate of 1.00. The median estimate represents a +656.18% increase from the last price of 0.60.
The current consensus among 7 polled investment analysts is to Buy stock in Orchard Therapeutics PLC. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.23
Reporting Date Nov 09
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.